Tyrosine kinase inhibitors

a clinical perspective.

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

Cancer treatment has so far been restricted to cytotoxic and hormonal agents. These have been of limited value in their efficacy and their toxicity profile. A new era of targeted therapies is rapidly evolving. A key target being actively pursued is the receptor tyrosine kinase. Several compounds that inhibit this target are in preclinical and clinical development. These compounds broadly fall into two categories: monoclonal antibodies and small-molecule inhibitors. The common targets are epidermal growth factor receptor, Bcr-Abl tyrosine kinase, vascular endothelial growth factor, fibroblast growth factor receptor, and platelet-derived growth factor. Two of these compounds, trastuzumab and imatinib mesylate, have been approved by the US Food and Drug Administration for use in specific indications. Other uses are being tested, such as imatinib for gastrointestinal stromal tumor. These compounds will alter cancer care as adjuncts to currently available treatment options.

Original languageEnglish (US)
Pages (from-to)9-19
Number of pages11
JournalCurrent Oncology Reports
Volume4
Issue number1
StatePublished - Jan 2002

Fingerprint

Protein-Tyrosine Kinases
bcr-abl Fusion Proteins
Fibroblast Growth Factor Receptors
Gastrointestinal Stromal Tumors
Platelet-Derived Growth Factor
Cytotoxins
Receptor Protein-Tyrosine Kinases
United States Food and Drug Administration
Epidermal Growth Factor Receptor
Vascular Endothelial Growth Factor A
Neoplasms
Monoclonal Antibodies
Imatinib Mesylate
Therapeutics
Trastuzumab

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Tyrosine kinase inhibitors : a clinical perspective. / Goel, Sanjay; Mani, Sridhar; Perez-Soler, Roman.

In: Current Oncology Reports, Vol. 4, No. 1, 01.2002, p. 9-19.

Research output: Contribution to journalArticle

@article{780509dd9dff4f488a237436e9462ab6,
title = "Tyrosine kinase inhibitors: a clinical perspective.",
abstract = "Cancer treatment has so far been restricted to cytotoxic and hormonal agents. These have been of limited value in their efficacy and their toxicity profile. A new era of targeted therapies is rapidly evolving. A key target being actively pursued is the receptor tyrosine kinase. Several compounds that inhibit this target are in preclinical and clinical development. These compounds broadly fall into two categories: monoclonal antibodies and small-molecule inhibitors. The common targets are epidermal growth factor receptor, Bcr-Abl tyrosine kinase, vascular endothelial growth factor, fibroblast growth factor receptor, and platelet-derived growth factor. Two of these compounds, trastuzumab and imatinib mesylate, have been approved by the US Food and Drug Administration for use in specific indications. Other uses are being tested, such as imatinib for gastrointestinal stromal tumor. These compounds will alter cancer care as adjuncts to currently available treatment options.",
author = "Sanjay Goel and Sridhar Mani and Roman Perez-Soler",
year = "2002",
month = "1",
language = "English (US)",
volume = "4",
pages = "9--19",
journal = "Current Oncology Reports",
issn = "1523-3790",
publisher = "Current Science, Inc.",
number = "1",

}

TY - JOUR

T1 - Tyrosine kinase inhibitors

T2 - a clinical perspective.

AU - Goel, Sanjay

AU - Mani, Sridhar

AU - Perez-Soler, Roman

PY - 2002/1

Y1 - 2002/1

N2 - Cancer treatment has so far been restricted to cytotoxic and hormonal agents. These have been of limited value in their efficacy and their toxicity profile. A new era of targeted therapies is rapidly evolving. A key target being actively pursued is the receptor tyrosine kinase. Several compounds that inhibit this target are in preclinical and clinical development. These compounds broadly fall into two categories: monoclonal antibodies and small-molecule inhibitors. The common targets are epidermal growth factor receptor, Bcr-Abl tyrosine kinase, vascular endothelial growth factor, fibroblast growth factor receptor, and platelet-derived growth factor. Two of these compounds, trastuzumab and imatinib mesylate, have been approved by the US Food and Drug Administration for use in specific indications. Other uses are being tested, such as imatinib for gastrointestinal stromal tumor. These compounds will alter cancer care as adjuncts to currently available treatment options.

AB - Cancer treatment has so far been restricted to cytotoxic and hormonal agents. These have been of limited value in their efficacy and their toxicity profile. A new era of targeted therapies is rapidly evolving. A key target being actively pursued is the receptor tyrosine kinase. Several compounds that inhibit this target are in preclinical and clinical development. These compounds broadly fall into two categories: monoclonal antibodies and small-molecule inhibitors. The common targets are epidermal growth factor receptor, Bcr-Abl tyrosine kinase, vascular endothelial growth factor, fibroblast growth factor receptor, and platelet-derived growth factor. Two of these compounds, trastuzumab and imatinib mesylate, have been approved by the US Food and Drug Administration for use in specific indications. Other uses are being tested, such as imatinib for gastrointestinal stromal tumor. These compounds will alter cancer care as adjuncts to currently available treatment options.

UR - http://www.scopus.com/inward/record.url?scp=0036134344&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036134344&partnerID=8YFLogxK

M3 - Article

VL - 4

SP - 9

EP - 19

JO - Current Oncology Reports

JF - Current Oncology Reports

SN - 1523-3790

IS - 1

ER -